In Table 2 of the original article published online, the response rates achieved with terlipressin and noradrenaline as described by reference 197 were incorrectly stated to be 70% and 83%, whereas they should have been 83% and 70%. In addition, a footnote has now been added to Table 2 to indicate studies that included patients with HRS-2. Finally, the overall reversal rates achieved with terlipressin based on studies outside the USA, which were described in the original article to range from ~40-70%, have been corrected to ~40-80%. These corrections have been made to the HTML and PDF versions of the manuscript.
